A cocaine hydrolase engineered from human butyrylcholinesterase selectively blocks cocaine toxicity and reinstatement of drug seeking in rats

Neuropsychopharmacology

Volumn 33, Issue 11, 2008, Pages 2715-2725

  Brimijoin, Stephen ^a   Gao, Yang ^a   Anker, Justin J ^b   Gliddon, Luke A ^b   LaFleur, David ^c   Shah, R ^c   Zhao, Qinghai ^c   Singh, M ^c   Carroll, Marilyn E ^b  

^a MAYO GRADUATE SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Drug Development   (United States)

Author keywords

Addiction relapse; Albumin fusion proteins; Cocaine overdose rescue; Drug self administration rodent model; Operant conditioning; Protein based therapeutics for cocaine abuse

Indexed keywords

CHOLINESTERASE; COCAINE HYDROLASE; HYDROLASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; COCAINE DEPENDENCE; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; ENZYME ENGINEERING; FEMALE; GENE MUTATION; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; SEIZURE; TREATMENT INDICATION;

ANIMALS; BEHAVIOR, ADDICTIVE; BUTYRYLCHOLINESTERASE; CHO CELLS; COCAINE; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; HYDROLASES; MALE; MOTOR ACTIVITY; PROTEIN ENGINEERING; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SELF ADMINISTRATION;

EID: 48749118846     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301666     Document Type: Article

References (53)

1. Anker JJ, Larson EB, Gliddon LA, Carroll ME (2007). Effects of progesterone and estrogen on reinstatement of cocaine-seeking behavior in female rats. Exp and Clin Psychopharm 15: 472-480.
2. Baird TJ, Deng SX, Landry DW, Winger G, Woods JH (2000). Natural and artificial enzymes against cocaine. I. Monoclonal antibody 15A10 and the reinforcing effects of cocaine in rats. J Pharmacol Exp Ther 295: 1127-1134.
3. Bresler M, Rosser S, Basran A, Bruce N (2000). Gene cloning and nucleotide sequencing and properties of a cocaine esterase from Rhodococcus sp. strain MB1. Appl Environ Microbiol 66: 904-908.
4. Brimijoin S, Shen M, Sun H (2002). Radiometric solvent-partitioning assay for screening cocaine hydrolases and measuring cocaine levels in milligram tissue samples. Anal Biochem 309: 200-205.
5. Briscoe RJ, Jeanville PM, Cabrera C, Baird TJ, Woods JH, Landry DW (2001). A catalytic antibody against cocaine attenuates cocaine's cardiovascular effects in mice: A dose and time course analysis. Int Immunopharmacol 1: 1189-1198.
6. Carmona G, Jufer R, Goldberg S, Gorelick D, Greig N, Yu Q et al (2000). Butyrylcholinesterase accelerates cocaine metabolism: In vitro and in vivo effects in nonhuman primates and humans. Drug Metab Dispos 28: 367-371.
7. Carrera MR, Trigo JM, Wirsching P, Roberts AJ, Janda KD (2005). Evaluation of the anticocaine monoclonal antibody GNC92H2 as an immunotherapy for cocaine overdose. Pharmacol Biochem Behav 81: 709-714.
8. Carroll ME, Campbell UC (2000). A behavioral economic analysis of the reinforcing effects of drugs: Transition states of addiction., In: Bickel WK and Vuchinich R (eds). Reframing Health Behavior Change with Behavioral Economics. Lawrence Erlbaum Associates: New Jersey. pp 63-87.
9. Carroll ME, Comer SD (1996). Animal models of relapse. Exp Clin Psychopharmacol 4: 11-18.
10. Cascio C, Comite C, Ghiara M, Lanza G, Ponchione A (1988). Use of serum cholinesterases in severe organophosphorus poisoning. Our experience. Minerva Anestesiol 54: 337-338.
11. Cashman JR, Berkman CE, Underiner GE (2000). Catalytic antibodies that hydrolyze (-)-cocaine obtained by a high-throughput procedure. J Pharmacol Exp Ther 293: 952-961.
12. Clark MG, Sun W, Myers TM, Bansal R, Doctor BP, Saxena A (2005). Effects of physostigmine and human butyrylcholinesterase on acoustic startle reflex and prepulse inhibition in C57BL/6J mice. Pharmacol Biochem Behav 81: 497-505.
13. Comer SD, Lac ST, Wyvell CL, Curtin LK, Carroll ME (1995). Food deprivation affects extinction and reinstatement of resonding in rats. Psychopharmacology 121: 150-157.
14. Cooper ZD, Narasimhan D, Sunahara RK, Mierrzejewski P, Jutkiewicz EM, Larsen NA et al (2006). Rapid and robust protection against cocaine-induced lethality in rats by the bacterial cocaine esterase. Mol Pharmacol 70: 1885-1891.
15. Doctor BP, Saxena A (2005). Bioscavengers for the protection of humans against organophosphate toxicity. Chem Biol Interact 157-158: 167-171.
16. Duttaroy A, Kanakarai P, Osborn BL, Schneider H, Pickeral OK, Chen C et al (2005). Development of a long-acting insulin analog using albumin fusion technology. Diabetes 54: 251-258.
17. Gao Y, Brimijoin S (2004). An engineered cocaine hydrolase blunts and reverses cardiovascular responses to cocaine in rats. J Pharmacol Expt Ther 310: 1046-1052.
18. Gao Y, Brimijoin S (2005). Visualizing viral transduction of a cocaine-hydrolyzing, human butyrylcholinesterase in rats. Chem Biol Interact 157-158: 97-103.
19. Gao Y, Brimijoin S (2006). Viral transduction of cocaine hydrolase in brain reward centers. Cell Mol Neurobiol 26: 355-361.
20. Gorelick D (1997). Enhancing cocaine metabolism with butyrylcholinesterase as a treatment strategy. Drug Alcohol Depend 48: 159-165.
21. Hoffman R, Morasco R, Goldfrank L (1996). Administration of purified human plasma cholinesterase protects against cocaine toxicity in mice. J Toxicol Clin Toxicol 34: 259-266.
22. Hoffman RS, Henry GC, Howland MA, Weisman RS, Weil L, Goldfrank LR (1992). Association between life-threatening cocaine toxicity and plasma cholinesterase activity. Ann Emer Med 21: 247-253.
23. Inaba T, Stewart D, Kalow W (1978). Metabolism of cocaine in man. Clin Pharmacol Ther 23: 547-552.
24. Kalivas PW, Volkow ND (2005). The neural basis of addiction: A pathology of motivation and choice. Am J Psychiatry 162: 1403-1413.
25. Ko MC, Bowen LD, Narsimhan D, Berlin AA, Lukacs NW, Sunahara RK et al (2007). Cocaine esterase: Interactions with cocaine and immune responses in mice. J Pharmacol Exp Ther 320: 926-933.
26. Landry DW, Zhao K, Yang GX-Q, Glickman M, Georgiadis TM (1993). Antibody-catalyzed degradation of cocaine. Science 259: 1899-1901.
27. Larsen N, Turner J, Stevens J, Rosser S, Basran A, Lerner R et al (2002). Crystal structure of a bacterial cocaine esterase. Nature Struct Biol 9: 17-20.
28. Larson EB, Roth ME, Anker JJ, Carroll ME (2005). Effect of short-vs. long-term estrogen on reinstatement of cocaine-seeking behavior in female rats. Pharmacol Biochem Behav 82: 98-108.
29. Lynch T, Mattes C, Singh A, Bradley R, Brady R, Dretchen K (1997). Cocaine detoxification by human plasma butyrylcholinesterase. J Appl Pharmacol 145: 363-371.
30. Lynch WJ, Carroll ME (2000). Reinstatement of cocaine self-administration in rats: Sex differences. Psychopharmacology 148: 196-200.
31. Madden J, Powers R (1990). Effects of cocaine and cocaine metabolites on cerebral arteries in vitro. Life Sci 47: 1109-1114.
32. Marzuk P, Tardiff K, Leon A, Hirsch C, Stajic M, Portera L et al (1995). Fatal injuries after cocaine use as a leading cause of death among young adults in New York City. N Engl J Med 332: 1753-1757.
33. Maxwell DM, Castro CA, De La Hoz DM, Gentry MK, Gold MB, Solana RP et al (1992). Protection of rhesus monkeys against soman and prevention of performance decrement by pretreatment with acetylcholinesterase. Toxical Appl Pharmacol 115: 44-49.
34. McKenzie KM, Mee JM, Rogers CJ, Hixon MS, Kaufmann GF, Janda KD (2007). Identification and characterization of single chain anti-cocaine catalytic antibodies. J Mol Biol 365: 722-731.
35. Mets B, Winger G, Cabrera C, Seo S, Jamdar S, Yang G et al (1998). A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc Natl Acad Sci USA 95: 10176-10181.
36. 3H]benzoylecgonine and pharmacological activity of some cocaine metabolites. J Pharm Pharmacol 27: 784-786.
37. Mordenti J, Chen SA, Moore JA, Ferraiolo BL, Green JD (1991). Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm Res 8: 1351-1359.
38. National Research Council (2003). Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research. National Academies Press: Washington, DC.
39. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A et al (2002). Pharmacokinetic and pharmacodynamic studies of a human serum albumin-interferon-alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther 303: 540-548.
40. Pan Y, Gao D, Yang W, Cho H, Yang G, Tai HH et al (2005). Computational redesign of human butyrylcholinesterase for anticocaine medication. Proc Natl Acad Sci USA 102: 16656-16661.
41. Pancook JD, Pecht G, Ader M, M M, Lockridge O, Watkins JD (2003). Application of directed evolution technology to optimize the cocaine hydrlase activity of human butyrylcholineserase. FASEB J 17: A565.
42. Perry JL, Larson EB, German JP, Madden GJ, Carroll ME (2005). Impulsivity (delay discounting) as a predictor of acquisition of IV cocaine self-administration in female rats. Psychopharmacology (Berl) 178: 193-201.
43. Perry JL, Morgan AD, Anker JJ, Dess NK, Carroll ME (2006). Escalation of i.v. cocaine self-administration and reinstatement of cocaine-seeking behavior in rats bred for high and low saccharin intake. Psychopharmacology (Berl) 186: 235-245.
44. Piazza PV, Ferdico M, Russo D, Crescimanno G, Benigno A, Amato G (1989). Circling behavior: Ethological analysis and functional considerations. Behav Brain Res 31: 267-271.
45. Saxena A, Sun W, Luo C, Myers TM, Koplovitz I, Lenz DE et al (2006). Bioscavenger for protection from toxicity of organo-phosphorus compounds. J Mol Neurosci 30: 145-148.
46. Schrank K (1992). Cocaine-related emergency department presentations. NIDA Res Monogr 123: 110-128.
47. Shaham Y, Shalev U, Lu L, De Wit H, Stewart J (2003). The reinstatement model of drug relapse: History, methodology and major findings. Psychopharmacology (Berl) 168: 3-20.
48. Shalev U, Grimm JW, Shaham Y (2002). Neurobiology of relapse to heroin and cocaine: A review. Pharmacol Rev 54: 1-42.
49. Stewart DJ, Inaba T, Tang BK, Kalow W (1977). Hydrolysis of cocaine in human plasma by cholinesterase. Life Sci 20: 1557-1564.
50. Sun H, El Yazal J, Brimijoin S, Pang Y-P (2001). Predicted Michaelis-Menten complexes of cocaine-butyrylcholinesterase: Engineering effective butyrylcholinesterase mutants for cocaine detoxification. J Biol Chem 276: 9330-9336.
51. Sun H, Pang YP, Lockridge O, Brimijoin S (2002a). Re-engineering butyrylcholinesterase as a cocaine hydrolase. Mol Pharmacol 62: 220-224.
52. Sun H, Shen ML, Pang Y-P, Lockridge O, Brimijoin S (2002b). Cocaine metabolism accelerated by a re-engineered human butyrylcholinesterase. JPET 302: 710-716.
53. Turner JM, Larsen NA, Basran A, Barbas III CF, Bruce NC, Wilson IA et al (2002). Biochemical characterization and structural analysis of a highly proficient cocaine esterase. Biochemistry 41: 12297-12307.